These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Oral Cannabidiol does not Alter the Subjective, Reinforcing or Cardiovascular Effects of Smoked Cannabis. Haney M; Malcolm RJ; Babalonis S; Nuzzo PA; Cooper ZD; Bedi G; Gray KM; McRae-Clark A; Lofwall MR; Sparenborg S; Walsh SL Neuropsychopharmacology; 2016 Jul; 41(8):1974-82. PubMed ID: 26708108 [TBL] [Abstract][Full Text] [Related]
5. Urinary Pharmacokinetic Profile of Cannabidiol (CBD), Δ9-Tetrahydrocannabinol (THC) and Their Metabolites following Oral and Vaporized CBD and Vaporized CBD-Dominant Cannabis Administration. Sholler DJ; Spindle TR; Cone EJ; Goffi E; Kuntz D; Mitchell JM; Winecker RE; Bigelow GE; Flegel RR; Vandrey R J Anal Toxicol; 2022 May; 46(5):494-503. PubMed ID: 34089060 [TBL] [Abstract][Full Text] [Related]
6. Cannabidiol (CBD) content in vaporized cannabis does not prevent tetrahydrocannabinol (THC)-induced impairment of driving and cognition. Arkell TR; Lintzeris N; Kevin RC; Ramaekers JG; Vandrey R; Irwin C; Haber PS; McGregor IS Psychopharmacology (Berl); 2019 Sep; 236(9):2713-2724. PubMed ID: 31044290 [TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetic Profile of ∆9-Tetrahydrocannabinol, Cannabidiol and Metabolites in Blood following Vaporization and Oral Ingestion of Cannabidiol Products. Bergeria CL; Spindle TR; Cone EJ; Sholler D; Goffi E; Mitchell JM; Winecker RE; Bigelow GE; Flegel R; Vandrey R J Anal Toxicol; 2022 Jul; 46(6):583-591. PubMed ID: 35438179 [TBL] [Abstract][Full Text] [Related]
8. Effect of Cannabidiol and Δ9-Tetrahydrocannabinol on Driving Performance: A Randomized Clinical Trial. Arkell TR; Vinckenbosch F; Kevin RC; Theunissen EL; McGregor IS; Ramaekers JG JAMA; 2020 Dec; 324(21):2177-2186. PubMed ID: 33258890 [TBL] [Abstract][Full Text] [Related]
9. Can oral fluid cannabinoid testing monitor medication compliance and/or cannabis smoking during oral THC and oromucosal Sativex administration? Lee D; Karschner EL; Milman G; Barnes AJ; Goodwin RS; Huestis MA Drug Alcohol Depend; 2013 Jun; 130(1-3):68-76. PubMed ID: 23146820 [TBL] [Abstract][Full Text] [Related]
10. The impacts of potency, warning messages, and price on preferences for Cannabis flower products. Shi Y; Cao Y; Shang C; Pacula RL Int J Drug Policy; 2019 Dec; 74():1-10. PubMed ID: 31382201 [TBL] [Abstract][Full Text] [Related]
11. Δ9-Tetrahydrocannabinol and Cannabidiol Time Courses in the Sera of "Light Cannabis" Smokers: Discriminating Light Cannabis Use from Illegal and Medical Cannabis Use. Pichini S; Mannocchi G; Berretta P; Zaami S; Pirani F; Pacifici R; Busardò FP Ther Drug Monit; 2020 Feb; 42(1):151-156. PubMed ID: 31389860 [TBL] [Abstract][Full Text] [Related]
12. A randomised controlled trial of vaporised Δ Solowij N; Broyd S; Greenwood LM; van Hell H; Martelozzo D; Rueb K; Todd J; Liu Z; Galettis P; Martin J; Murray R; Jones A; Michie PT; Croft R Eur Arch Psychiatry Clin Neurosci; 2019 Feb; 269(1):17-35. PubMed ID: 30661105 [TBL] [Abstract][Full Text] [Related]
13. Randomized, double-blind, placebo-controlled study about the effects of cannabidiol (CBD) on the pharmacokinetics of Delta9-tetrahydrocannabinol (THC) after oral application of THC verses standardized cannabis extract. Nadulski T; Pragst F; Weinberg G; Roser P; Schnelle M; Fronk EM; Stadelmann AM Ther Drug Monit; 2005 Dec; 27(6):799-810. PubMed ID: 16306858 [TBL] [Abstract][Full Text] [Related]
14. Acute Pharmacokinetic Profile of Smoked and Vaporized Cannabis in Human Blood and Oral Fluid. Spindle TR; Cone EJ; Schlienz NJ; Mitchell JM; Bigelow GE; Flegel R; Hayes E; Vandrey R J Anal Toxicol; 2019 May; 43(4):233-258. PubMed ID: 30615181 [TBL] [Abstract][Full Text] [Related]
15. Assessment of Orally Administered Δ9-Tetrahydrocannabinol When Coadministered With Cannabidiol on Δ9-Tetrahydrocannabinol Pharmacokinetics and Pharmacodynamics in Healthy Adults: A Randomized Clinical Trial. Zamarripa CA; Spindle TR; Surujunarain R; Weerts EM; Bansal S; Unadkat JD; Paine MF; Vandrey R JAMA Netw Open; 2023 Feb; 6(2):e2254752. PubMed ID: 36780161 [TBL] [Abstract][Full Text] [Related]
16. Urinary Excretion Profile of Cannabinoid Analytes Following Acute Administration of Oral and Vaporized Cannabis in Infrequent Cannabis Users. Sholler DJ; Zamarripa CA; Spindle TR; Martin EL; Kuntz D; Vandrey R; Grabenauer M J Anal Toxicol; 2022 Oct; 46(8):882-890. PubMed ID: 35770374 [TBL] [Abstract][Full Text] [Related]
17. Acute effects of delta-9-tetrahydrocannabinol, cannabidiol and their combination on facial emotion recognition: a randomised, double-blind, placebo-controlled study in cannabis users. Hindocha C; Freeman TP; Schafer G; Gardener C; Das RK; Morgan CJ; Curran HV Eur Neuropsychopharmacol; 2015 Mar; 25(3):325-34. PubMed ID: 25534187 [TBL] [Abstract][Full Text] [Related]
18. Cannabidiol attenuates the appetitive effects of Delta 9-tetrahydrocannabinol in humans smoking their chosen cannabis. Morgan CJ; Freeman TP; Schafer GL; Curran HV Neuropsychopharmacology; 2010 Aug; 35(9):1879-85. PubMed ID: 20428110 [TBL] [Abstract][Full Text] [Related]
19. 'Standard THC units': a proposal to standardize dose across all cannabis products and methods of administration. Freeman TP; Lorenzetti V Addiction; 2020 Jul; 115(7):1207-1216. PubMed ID: 31606008 [TBL] [Abstract][Full Text] [Related]
20. Cannabinoid disposition in oral fluid after controlled smoked, vaporized, and oral cannabis administration. Swortwood MJ; Newmeyer MN; Andersson M; Abulseoud OA; Scheidweiler KB; Huestis MA Drug Test Anal; 2017 Jun; 9(6):905-915. PubMed ID: 27647820 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]